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Abstract
Objective: To update current estimates of non–device-associated pneumonia (ND pneumonia) 
rates and their frequency relative to ventilator associated pneumonia (VAP), and identify risk 
factors for ND pneumonia.
Design: Cohort study.
Setting: Academic teaching hospital.
Patients: All adult hospitalizations between 2013 and 2017 were included. Pneumonia (device 
associated and non–device associated) were captured through comprehensive, hospital-wide active 
surveillance using CDC definitions and methodology.
Results: From 2013 to 2017, there were 163,386 hospitalizations (97,485 unique patients) and 
771 pneumonia cases (520 ND pneumonia and 191 VAP). The rate of ND pneumonia remained 
stable, with 4.15 and 4.54 ND pneumonia cases per 10,000 hospitalization days in 2013 and 2017 
respectively (P = .65). In 2017, 74% of pneumonia cases were ND pneumonia. Male sex and 
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increasing age we both associated with increased risk of ND pneumonia. Additionally, patients 
with chronic bronchitis or emphysema (hazard ratio [HR], 2.07; 95% confidence interval [CI], 
1.40–3.06), congestive heart failure (HR, 1.48; 95% CI, 1.07–2.05), or paralysis (HR, 1.72; 95% 
CI, 1.09–2.73) were also at increased risk, as were those who were immunosuppressed (HR, 1.54; 
95% CI, 1.18–2.00) or in the ICU (HR, 1.49; 95% CI, 1.06–2.09). We did not detect a change in 
ND pneumonia risk with use of chlorhexidine mouthwash, total parenteral nutrition, all 
medications of interest, and prior ventilation.
Conclusion: The incidence rate of ND pneumonia did not change from 2013 to 2017, and 3 of 4 
nosocomial pneumonia cases were non–device associated. Hospital infection prevention programs 
should consider expanding the scope of surveillance to include non-ventilated patients. Future 
research should continue to look for modifiable risk factors and should assess potential prevention 
strategies.
Pneumonia is the most common healthcare-associated infection (HAI) in the United States, 
and it accounts for almost 25% of all hospital infections.1,2 Healthcare-associated 
pneumonia poses a substantial burden on the healthcare system, with 14% mortality and an 
estimated cost of >$3 billion per year.3,4 In the 1990s, 83% of healthcare-associated 
pneumonia cases were ventilator-associated (VAP); thus, the US Centers for Disease Control 
and Prevention (CDC) has traditionally focused surveillance efforts on VAP.3,5
Recent studies have reported dramatic decreases in VAP rates over the past 15 years6; 
however, the rate of non–device-associated pneumonia (ND pneumonia) remained stagnant 
during this period, and ND pneumonia now accounts for the majority of nosocomial 
pneumonia in hospitals settings.1,7–12 Despite this growing body of literature on the burden 
and importance of ND pneumonia in hospitals, little is known about the risk factors for 
infection, and there are currently no evidence-based guidelines for ND pneumonia 
prevention.13,14 In this study, we aimed to update current estimates of ND pneumonia rates 
and their frequency relative to VAP, to assess trends over time, and to identify potential risk 
factors.
Methods
Data sources and study population
Electronic medical records (EMRs) from adults (≥18 years old) admitted to the University of 
North Carolina (UNC) Hospitals between January 1, 2013, and December 31, 2017, were 
obtained from the Carolina Data Warehouse for Health (CDW-H), a central repository for 
clinical and administrative data from the UNC Healthcare System. Prisoners were excluded 
from analysis. Patients may have had multiple hospitalizations during the study period. HAIs 
were identified through the UNC Hospitals’ Epidemiology database, which included both 
device and non–device-associated HAIs, captured through comprehensive, hospital-wide 
active surveillance, in accordance with CDC case definitions and methodology.7,15 In July 
2014, the UNC Hospital Department of Epidemiology began also capturing ventilator-
associated events, a new surveillance concept that CDC developed as an alternative to 
traditional VAP surveillance.16 The 2 databases were then deterministically linked using 
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admission date, medical record numbers, and full name. This study was approved by the 
UNC Institutional Review Board.
Incidence of ND pneumonia
Quarterly incidence rates, per 10,000 hospitalization days, between 2013 and 2017 were 
calculated, and Poisson regression was used to assess a potential change in ND pneumonia 
rates over time. The proportion of pneumonia cases that were non–device related each year 
were also calculated. Cochran-Armitage trend tests (2-sided) were used to test the null 
hypothesis that the proportion of ND pneumonia cases did not change between 2015 and 
2017 (after new definitions were implemented).
Risk factors for ND pneumonia
Only hospitalizations between 2015 and 2017 with a length of stay (LOS) >2 days were 
included in risk-factor analyses. Potential risk factors of interest included patient sex, age, 
comorbidities, body mass index (BMI), immunosuppression (including neutropenia), 
modified early warning score (MEWS), Morse fall scale, and inpatient medication usage 
(specifically, anesthetics, antibiotics, antipsychotics, benzodiazepines, opioids, and acid 
suppressing medications), total parenteral nutrition (TPN), chlorhexidine mouthwash, prior 
endotracheal ventilation, prior tracheostomy, intensive care unit (ICU) stay, and trauma 
admission.
Patient comorbidities were captured using the discharge diagnosis codes from the 
International Classification of Disease, Ninth Revision, Clinical Modification (ICD-9-CM) 
(January 2015–September 2015) and the ICD-10-CM (October 2015–December 2017) on 
each record. Deyo et al (1992)17 and Quan et al (2005)18 algorithms were adapted to identify 
components of the Charlson comorbidity index (CCI) score (Supplemental Table 1 online). 
Diagnosis codes for incident events (eg, acute myocardial infarction) were removed from all 
component definitions.17 Peripheral vascular disease (PVD) was also excluded due to low 
incidence (n = 201), and both malignancy (solid tumor or metastatic disease) and human 
immunodeficiency viruses (HIV) were incorporated into the broader classification of 
immunocompromised. Additionally, chronic pulmonary diseases were broken into more 
discrete categories: chronic bronchitis/emphysema, asthma, bronchiectasis, and other/
unspecified chronic obstructive pulmonary diseases (COPD).
Immunocompromised patients were identified using the Advisory Committee on 
Immunization Practices (ACIP) and Infectious Diseases Society of America (IDSA) 
guidelines on which persons cannot receive live-attenuated vaccinations.19 Diagnoses of 
immunosuppressive conditions, which included HIV, neutropenia, organ transplant, and 
malignancy, were identified using discharge diagnosis codes, and relevant ICD-9-CM codes 
were identified using the Greenberg et al (2016)20 algorithm. The ICD-10-CM codes were 
identified using Centers for Medicare and Medicaid Services (CMS) generalized equivalence 
mapping (Supplemental Table 1 online). Patients receiving chemotherapeutic agents, 
corticosteroids, or immune-modulating agents within the first 2 days of their hospitalization 
were identified using inpatient medications (Supplemental Table 2 online). Neutropenia was 
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identified using both diagnosis codes and laboratory blood test results within the first 2 
hospitalization days (defined as ≥2 white blood cell [WBC] counts <500 cells/mm3).
The severity of illness and frailty were measured using the MEWS21 and Morse fall scale,
22,23 respectively. These metrics are both automatically calculated within the UNC Hospitals 
EMR. For the MEWS, specific vital signs are used to identify patients at risk for imminent 
deterioration: systolic blood pressure, heart rate, respiratory rate, temperature, conscious 
level, and hourly urine output (for 2 hours). The Morse fall scale includes history of falling, 
number of secondary diagnoses, whether ambulatory aid is needed, intravenous therapy/
heparin lock, gait, and mental status. It is used to predict future falls in hospitalized patients. 
For each patient, the first MEWS and Morse fall scale score within the first 2 days of 
admission was captured and categorized using the clinically relevant cutoff points: MEWS, 
<1 (reference), 2, 3, ≥4 and Morse fall scale, 0 (reference), 1–24, 25–45, >45. A MEWS ≥4 
and a Morse fall scale score >45 were both considered indicators of severe illness.
We treated ICU stay, inpatient medications, chlorohexidine mouthwash, TPN, and 
mechanical ventilation as time-varying exposures, and we considered the patient exposed for 
the remainder of the hospitalization. For example, once a patient received antibiotics on day 
4, they would be considered exposed from day 4 until discharge and classified as unexposed 
on days 1–3. All medications were identified using orders captured in the EMR, and receipt 
was confirmed using the medication administration record (Supplemental Table 2 online).
Multivariable Cox proportional hazards regression was used to simultaneously estimate the 
association between each potential risk factor and the incidence of ND pneumonia. 
Correlation between repeat hospitalizations of the same patients were taken into account by 
utilizing robust sandwich covariance matrix estimates as described by Lee et al (1992).24 
Both VAP and inpatient mortality were treated as competing risks using the Fine and Gray 
(1999)25 model.
Due to missing BMI values (n = 15,146, 17%), MEWS (n = 18,761, 21%), Morse fall scale 
(n = 8,571, 10%), and location/discharge disposition (n = 8,482, 10%), inverse probability of 
missing weights (IPMW) were calculated.26 Weights were estimated using multivariable 
logistic regression, which modeled the probability of being a complete case as a function of 
the year and season of admission, cause of admission, patient age, sex, Charlson score 
comorbidities (excluding HIV and cancer), immunosuppression, TPN, medication usage 
anytime during hospitalization (antibiotics, antipsychotics, local anesthetics, general 
anesthetics, benzodiazepines, opioids, alpha-2 agonists, nonsteroidal anti-inflammatory 
drugs [NSAIDs], calcium channel blockers, statins, angiotensin converting enzyme [ACE] 
inhibitors, angiotensin II receptor blockers [ARBs], histamine-2 agonists, proton pump 
inhibitors), device use (urinary catheter, ventilator, central venous catheter, peripheral 
venous catheter), whether they underwent any surgery (CPT 10021 – 69990), and LOS, as 
well as interaction terms between admission timing and both cause of admission and LOS. 
Age and LOS were modeled as restricted quadratic splines.27 Because 99% of 
hospitalizations from January through March 2015 were missing MEWS (28% of all 
missing), all hospitalizations in this time period were excluded.
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Our statistical analysis strategy is consistent with the American Statistical Association’s 
statements on P values.28,29 All statistical computations were performed using SAS version 
9.4 software (SAS Institute, Cary, NC).
Results
From 2013 to 2017, there were 163,386 hospitalizations (97,485 unique patients) and 771 
cases of healthcare-associated pneumonia (520 ND pneumonia and 191 VAP) during 666 
unique hospitalizations at UNC Hospitals. Of the 771 pneumonia cases, 768 (99.6%) were 
successfully linked to a hospitalization record. Of hospitalizations, 87% (n = 142,836) were 
>2 days (median, 5 days; interquartile range [IQR], 3–8 days). Patient demographics and 
causes of admission are described in Table 1.
Median time to diagnosis was 9 days for ND pneumonia (IQR, 5–19) and 11 days for VAP 
(IQR, 6–21). Between 2013 and 2017, the rate of ND pneumonia was stable, with 4.15 ND 
pneumonia cases per 10,000 hospitalization days in 2013 and 4.54 ND pneumonia cases per 
10,000 hospitalization days in 2017 (P = .65) (Fig. 1A). In 2013–2014 (prior to the 
implementation of the CDC’s updated definition for VAP), >80% of pneumonia cases were 
non–device associated. Between 2015 and 2017 (after the CDC ventilator-associated event 
definition was implemented), the proportion of non–device infections ranged from 64% to 
74% (P = .09) (Fig. 1B). From 2015 to 2017, only 36% (n = 107) of ND pneumonia cases 
occurred in the ICU; 45% (n = 137) occurred on a floor; and 18% occurred on a stepdown 
unit (n = 55) (25 events could not be attributed to a specific location due to missing location 
data). In comparison, 96% of all VAPs occurred in an ICU (n = 140); however, this 
represents only 57% of all pneumonia cases in ICUs. The 30-day and 60-day cumulative 
incidences of ND pneumonia were 19.7 and 41.7 infections per 10,000 patients, respectively 
(Fig. 2).
There were 88,487 hospitalizations between 2015 and 2017 with an LOS >2 days included 
in the risk factor analysis. Median IPMW was 1.07 (IQR, 1.03–1.24; range 1.00–21.38), and 
only 27 hospitalizations had a weight >10. After adjustment, male sex and older age were 
associated with increased incidence of ND pneumonia (Table 2). Additional risk factors 
included diagnoses for bronchitis or emphysema (hazard ratio [HR], 2.07; 95% confidence 
interval [CI], 1.40–3.06), congestive heart failure (HR, 1.48; 95% CI, 1.07–2.05), paralysis 
(HR, 1.72; 95% CI, 1.09–2.73), and immunosuppression (HR, 1.54; 95% CI, 1.18–2.00). 
Being in an ICU was also associated with increased ND pneumonia (HR, 1.49; 95% CI, 
1.06–2.09). Conversely, patients with dementia were at lower risk of infection (HR, 0.41; 
95% CI, 0.18–0.95). We did not detect a change in ND pneumonia risk for the following 
variables: use of chlorhexidine mouthwash, TPN, illness severity measures, all medications 
of interest, and prior ventilation variables. For chlorhexidine mouthwash, for example, 
although the hypothesis test of “HR = 1” was inconclusive, the point and interval estimates 
(HR, 0.90; 95% CI, 0.54–1.52) indicated that the data were compatible with hazard ratios as 
small as 0.54 and as large as 1.52 in the target population.29
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Between 2013 and 2017, the rate of ND pneumonia cases remained constant in UNC 
Hospitals, and non–device infections continue to account for most hospital-associated 
pneumonia cases. Risk factors for ND pneumonia included male sex, older age, ICU 
admission, and chronic bronchitis/emphysema, congestive heart failure, paralysis, and 
immunosuppression. To the best of our knowledge, this is the most comprehensive analysis 
of ND pneumonia rates and risk factors in an acute-care setting.
The incidence and proportion of ND pneumonia cases in our study are similar to rates 
reported by other centers. Davis and Finley,9 for example, utilized state-mandated 
comprehensive surveillance data from Pennsylvania and found that 71% of cases of 
pneumonia between 2009 and 2011 were non–device associated (5,597 ND pneumonia, 
2,299 VAP). In a 2014 convenience sample of 21 hospitals across the United States, the rate 
of ND pneumonia ranged from 0.12 to 2.28 cases per 1,000 patient days.11 Our findings are 
also consistent with a prior report from our institution. Between 2008 and 2012, the 
proportion of non–device-associated pneumonia cases increased from roughly 40% to 60%, 
predominantly due a decrease in device-associated infections without concomitant change in 
the incidence of non–device-associated infections.8
Older age, pulmonary disease, and ICU stays have been associated with increased risk of 
VAP.30 In our study, these same risk factors extended to ND pneumonia as well, albeit with 
some slight differences. Middle-aged adults (40–49 and 50–59 years old) were at higher risk 
than patients 18–39 years old, and only specific types of pulmonary disease (bronchitis and 
emphysema) had an increased risk (differences in ND pneumonia risk among patients with 
asthma, bronchiectasis, and other/unspecified COPD were not detected). In our study, 
paralysis was associated with increased incidence of ND pneumonia. Paralytic agents and 
coma/stupor have been associated with VAP, suggesting that limited mobility may increase a 
patient’s risk.30,31 Patients with paralysis may also have other neurological issues (eg, 
impaired swallowing or decreased level of consciousness) that could also account for the 
increased pneumonia risk. Male sex, chronic pulmonary disease, and congestive heart failure 
have also been shown to increase the risk of community-acquired pneumonia in older adults.
32 Overall, these finding suggest that certain characteristics may predispose some adults to 
healthcare-associated pneumonia.
Interestingly, we did not detect an association between acid-suppressing medication (ie, 
histamine-2 agonists and proton pump inhibitors [PPIs]), although they have been associated 
with increased risk of VAP.30 However, the literature for VAP is mixed. Additionally, 
evidence-based guidelines and awareness of potential adverse effects have narrowed 
indications for acid suppression therapies in the acute-care setting, and UNC Hospitals 
implemented changes to the clinical guidelines for stress ulcer prophylaxis prior to the study 
period. Similarly, antipsychotics have also been associated with aspiration pneumonia in 
both the hospital33 and community setting,34 but we did not detect an association between 
antipsychotic use and ND pneumonia.
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A few recent studies have reported that the use of oral care prevented ND pneumonia in 
high-risk patients (eg, neurologic injury patients, older adults).35–37 Although we did not 
detect an association between chlorhexidine mouthwash and ND pneumonia rates, this 
discrepancy could be due to targeted use of oral care with chlorhexidine at UNC Hospitals. 
In contrast to its universal use in prior studies, only 8% of hospitalized patients included in 
this analysis received this treatment. These individuals may have been selected to receive 
oral care with chlorhexidine specifically due to perceived higher risk for respiratory 
infections (although indication for chlorhexidine could not be determined), which could 
explain our inconclusive finding. Chlorhexidine mouthwash has also been associated with 
increased inpatient mortality.38 Studies assessing the utility of chlorhexidine mouthwash and 
oral care with VAP are mixed, and currently there are no recommendations on its use for 
device-associated infections.6
This study has several limitations. First, we were unable to assess causality, and the risk 
factors we identified may only be indicators for the true underlying mechanisms. Second, 
this was a single-center study and our results may not generalize to other hospitals, 
particularly if the patient population is different. We also did not account for duration, dose, 
or underlying indications for medication use. Additionally, ICD-9-CM and ICD-10-CM 
codes were used to identify comorbidities. Using these codes likely underestimates the 
prevalence of comorbidities, although we expect this misclassification to be nondifferential 
and, if anything, to bias results toward the null. Similarly, ND pneumonia and VAP were 
captured using CDC definitions, some of which require laboratory confirmation, and 
patients who are treated for suspected pneumonia but are not cultured would be missed. 
Finally, although we had a large sample size, the incidence of ND pneumonia and prevalence 
of some risk factors were low, resulting in low levels of precision of the estimators as 
indicated by the widths of the observed confidence intervals.
In conclusion, between 2013 and 2017, the incidence rate of ND pneumonia was unchanged, 
and non–device infections represent the majority of healthcare-associated pneumonia cases 
in our acute-care hospital. Our study and similar findings by others suggest that hospital 
infection prevention programs should consider expanding the scope of surveillance and 
prevention programs to include nonventilated patients. Male sex, older age, bronchitis/
emphysema, congestive heart failure, paralysis, immunosuppression, and ICU stays were all 
associated with increased risk of ND pneumonia. Future research should continue to look for 
modifiable risk factors and assess potential prevention strategies.
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(A) Quarterly rates of non–device-associated pneumonia (ND pneumonia), per 10,000 
hospitalization days. (B) Proportion of hospital-associated pneumonia that are device 
associated and non–device associated, stratified by year.
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Stacked cumulative incidences of non–device-associated pneumonia (ND pneumonia, gray) 
and ventilator-associated (VAP, white) pneumonia.
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Total hospitalizations, no. 62,853 100,533
Unique patients, no. 41,941 64,633
Female, no. (%) 35,360 (56) 55,985 (56)
Age, median y (IQR) 52 (34 – 66) 53 (35 – 66)
Race, no. (%)
 White 37,766 (62) 60,089 (62)
 Black 16,625 (27) 26,378 (27)
 Asian 752 (1) 1,411 (1)
 Hawaiian/Pacific Islander 31 (<1) 79 (<1)
 Native American 533 (1) 908 (1)
 Other race 5,159 (8) 8,166 (8)




 Circulatory disease 8,166 (13) 13,440 (14)
 Injury or poisoning
b 8,429 (13) 12,934 (13)
 Childbirth/complications of pregnancy 7,938 (13) 12,408 (13)
 Digestive disease 5,982 (10) 10,367 (11)
 Neoplasms 6,094 (10) 9,882 (10)
 Psychological disorders 4,485 (7) 6,738 (7)
 Infectious/parasitic disease 3,651 (6) 5,789 (6)
 Respiratory disease 2,977 (5) 4,674 (5)
 Musculoskeletal disease 2,286 (4) 4,462 (5)
 Endocrine/metabolic disease 1,959 (3) 3,233 (3)
 Genitourinary disease 2,106 (3) 3,313 (3)
 Nervous system disease 1,679 (3) 2,756 (3)
 Skin disease 1,116 (2) 1,778 (2)
 Blood disease 994 (2) 1,575 (2)
 Other or ill-defined 4,862 (8) 4,972 (5)
LOS, median d (IQR) 5 (3–8) 5 (3–8)
Note. IQR, interquartile range; LOS, length of stay.
a
Classified using primary diagnosis on each hospitalization; 2,341 hospitalizations (1%) were unable to be linked to their diagnosis codes
b
A subset of these codes were used to identify trauma admissions.
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